{"title":"n -亚硝基吡咯烷的致癌性:大鼠剂量反应研究。","authors":"R Preussmann, D Schmähl, G Eisenbrand","doi":"10.1007/BF00285322","DOIUrl":null,"url":null,"abstract":"<p><p>Results from a dose-response study in rats are reported, in which daily oral doses of 10, 3, 1, and 0.3 mg/kg bodyweight/day respectively were administered. The three highest dose levels resulted in incidences of liver cancer of 46, 84, and 32% respectively. In the lowest dose group (0.3 mg/kg/day) no statistically significant increase in tumor rate compared to untreated controls was found.</p>","PeriodicalId":76850,"journal":{"name":"Zeitschrift fur Krebsforschung und klinische Onkologie. Cancer research and clinical oncology","volume":"90 2","pages":"161-6"},"PeriodicalIF":0.0000,"publicationDate":"1977-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF00285322","citationCount":"9","resultStr":"{\"title\":\"Carcinogenicity of N-nitrosopyrrolidine: dose-response study in rats.\",\"authors\":\"R Preussmann, D Schmähl, G Eisenbrand\",\"doi\":\"10.1007/BF00285322\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Results from a dose-response study in rats are reported, in which daily oral doses of 10, 3, 1, and 0.3 mg/kg bodyweight/day respectively were administered. The three highest dose levels resulted in incidences of liver cancer of 46, 84, and 32% respectively. In the lowest dose group (0.3 mg/kg/day) no statistically significant increase in tumor rate compared to untreated controls was found.</p>\",\"PeriodicalId\":76850,\"journal\":{\"name\":\"Zeitschrift fur Krebsforschung und klinische Onkologie. Cancer research and clinical oncology\",\"volume\":\"90 2\",\"pages\":\"161-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1977-11-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/BF00285322\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zeitschrift fur Krebsforschung und klinische Onkologie. Cancer research and clinical oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/BF00285322\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zeitschrift fur Krebsforschung und klinische Onkologie. Cancer research and clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF00285322","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Carcinogenicity of N-nitrosopyrrolidine: dose-response study in rats.
Results from a dose-response study in rats are reported, in which daily oral doses of 10, 3, 1, and 0.3 mg/kg bodyweight/day respectively were administered. The three highest dose levels resulted in incidences of liver cancer of 46, 84, and 32% respectively. In the lowest dose group (0.3 mg/kg/day) no statistically significant increase in tumor rate compared to untreated controls was found.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
